Results 41 to 50 of about 99,547,245 (298)

Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody [PDF]

open access: yes, 2018
CTLA-4 and CD28 exemplify a co-inhibitory and co-stimulatory signaling axis that dynamically sculpts the interaction of antigen-specific T cells with antigen-presenting cells.
Nicholas S Wilson   +61 more
core   +1 more source

Beyond T-Cells: Functional Characterization of CTLA-4 Expression in Immune and Non-Immune Cell Types

open access: yesFrontiers in Immunology, 2020
The immune response consists of a finely-tuned program, the activation of which must be coupled with inhibitory mechanisms whenever initiated. This ensures tight control of beneficial anti-pathogen and anti-tumor responses while preserving tissue ...
Damilola Oyewole-Said   +9 more
doaj   +1 more source

Expression of CTLA‐4 by Human Monocytes [PDF]

open access: yesScandinavian Journal of Immunology, 2002
Cytotoxic T lymphocyte‐associated molecule‐4 (CTLA‐4) is a receptor present on T cells that plays a critical role in the downregulation of antigen‐activated immune responses. CTLA‐4 interacts with the ligands CD80 and CD86 on antigen‐presenting cells (APC), and also directs the assembly of inhibitory signalling complexes that lead to quiescence or ...
X-B, Wang   +5 more
openaire   +2 more sources

Anti-PD-1 and anti-CTLA-4 treatment of HepFrag tumors.

open access: yes, 2019
A, Treatment schedule: anti-PD-1 (10 mg/kg, i.p.) and anti-CTLA-4 (5 mg/kg, i.p.) therapy started at day 25 after fragment implantation and was applied in 3 doses at days 0, 3 and 7.
Veronika Schandl (6941093)   +10 more
core   +1 more source

The role of T cell trafficking in CTLA-4 blockade-induced gut immunopathology

open access: yesBMC Biology, 2020
Background Immune checkpoint inhibitor (ICPI) can augment the anti-tumour response by blocking negative immunoregulators with monoclonal antibodies. The anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibody is the first ICPI which has shown ...
Shashuang Zhang   +4 more
doaj   +1 more source

CTLA-4 trafficking and surface expression [PDF]

open access: yesTrends in Immunology, 2008
The T-cell co-receptor cytotoxic T-cell antigen 4 (CTLA-4) has a strong inhibitory role as shown by the lymphoproliferative phenotype of CTLA-4-deficient mice. Despite its potent effects on T-cell function, CTLA-4 is primarily an intracellular antigen whose surface expression is tightly regulated by restricted trafficking to the cell surface and rapid ...
Elke, Valk   +2 more
openaire   +2 more sources

برهمکنش های مولکولی بین CTLA-4 و CD80/CD86 در تنظیم پاسخ های ایمنی: مقاله مروری [PDF]

open access: yesMajallah-i Dānishkadah-i Pizishkī-i Dānishgāh-i ̒ Ulūm-i Pizishkī-i Mashhad.
یکی از اصلی ترین مکانیسم های تنظیم پاسخ های ایمنی برهم کنش متقابل CTLA-4 و CD80/CD86 است. CTLA-4 نوعی رسپتور مهاری و دارای لیگاندهای CD80/CD86 و مشترک با گیرنده کمک محرک CD28 است. CTLA-4 طی فرآیندی به نام ترانس ‌اندوسیتوزیس این لیگاندها را اندوسیتوز کرده
زهرا درویش خلیل آبادی   +2 more
doaj   +1 more source

Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes

open access: yesBiomedical Journal, 2021
Autoimmune lymphoproliferative syndrome (ALPS) is an inherited non-malignant and non-infectious lymphoproliferative syndrome caused by mutations in genes affecting the extrinsic apoptotic pathway (FAS, FASL, CASP10).
Laura Gámez-Díaz, Bodo Grimbacher
doaj   +1 more source

CTLA-4

open access: yes, 2019
ALPSOY, ERKAN/0000-0001-7049-0170; uzun, soner/0000-0001-7059-5474; gunasti topal, suhan/0000-0003-0467-5884;
Bacanli, Ali   +6 more
openaire   +2 more sources

No evidence of a significant role for CTLA-4 in multiple sclerosis [PDF]

open access: yes, 2006
Variation in the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene plays a significant role in determining susceptibility to autoimmune thyroid disease and type 1 diabetes. Its role in multiple sclerosis is more controversial. In order to explore
Maranian, M   +7 more
core  

Home - About - Disclaimer - Privacy